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Abstract
Alzheimer’s disease (AD) is an age-related disorder that affects cognition. Our previous studies showed that the neuroprotective fragment of amyloid procurer protein (APP) metabolite, soluble APPa (sAPPa), interferes with b-site APP-cleaving
enzyme 1 (BACE1, b-secretase) cleavage and reduces amyloid-b (Ab) generation. In an attempt to identify approaches to
restore sAPPa levels, we found that human cord blood serum (CBS) significantly promotes sAPPa production compared with
adult blood serum (ABS) and aged blood serum (AgBS) in Chinese hamster ovary cells stably expressing wild-type human APP.
Interestingly, CBS selectively mediated the a-secretase cleavage of human neuron-specific recombinant APP695 in a cell-free
system independent of tumor necrosis factor-a converting enzyme (TACE; a disintegrin and metalloproteinase domaincontaining protein 17 [ADAM17]) and ADAM. Subsequently, using 3-step chromatographic separation techniques (i.e., diethylaminoethanol, size-exclusion, and ion-exchange chromatography), we purified and ultimately identified a CBS-specific
fraction with enhanced a-secretase catalytic activity (termed aCBSF) and found that aCBSF has more than 3,000-fold
increased a-secretase catalytic activity compared with the original pooled CBS. Furthermore, intracerebroventricular
injection of aCBSF markedly increased cerebral sAPPa levels together with significant decreases in cerebral Ab production
and abnormal tau (Thr231) phosphorylation compared with the AgBS fraction with enhanced a-secretase activity (AgBSF)
treatment in triple transgenic Alzheimer’s disease (3xTg-AD) mice. Moreover, AgBSF administered intraperitoneally
to transgenic mice with five familial Alzheimer’s disease mutations (5XFAD) via an osmotic mini pump for 6 weeks (wk)
ameliorated b-amyloid plaques and reversed cognitive impairment measures. Together, our results propose the necessity for
further study aimed at identification and characterization of a-secretase in CBS for novel and effective AD therapy.
Keywords
Alzheimer’s disease, amyloid-b, cord blood serum, human umbilical cord blood cell, soluble amyloid precursor protein a, tau

Introduction
The neuropathological hallmarks of Alzheimer’s disease
(AD) that differentiate it from other types of dementia
include extracellular b-amyloid plaques composed largely
of amyloid-b (Ab) peptides1 and intracellular neurofibrillary
tangles (NFTs) composed of the hyperphosphorylated
microtubule-associated protein tau2. Successive cleavage
of amyloid procurer protein (APP) by b- and g-secretases
produces Ab peptides of variable length (Abx-40, 42), soluble
APPb, membrane-bound b-C-terminal fragment (b-CTF,
C99), and APP intracellular cytoplasmic/C-terminal domain
(AICD)3. The Ab peptide fragments, which accumulate as
plaques in the brain, induce neuroinflammation, synaptic
dysfunction, and neuronal cell death that affects cognitive
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function4. In contrast, most of the APP is cleaved by a- and
g-secretases that not only preclude Ab generation but also
produce a secreted soluble APPa (sAPPa), membrane-bound
a-CTF (a-CTF, C83), P3 peptide, and AICD5. Overall,
sAPPa has been shown to be involved in numerous physiological functions in the brain, which appear to be interrupted
in AD. Several studies have shown that neurotrophic fragment sAPPa not only prevents Ab generation6 and tau phosphorylation7 but is also known to be a neuroprotective APP
metabolite including but not limited to proliferation, neurite
outgrowth, and long-term potentiation 8–10 . Thus, we
hypothesized that therapeutic interventions or approaches
that have potential to produce sAPPa markedly could
improve AD pathology and cognitive function.
Several studies have shown that human umbilical cord
blood cells (HUCBCs) have therapeutic potential in numerous age-related neuroinflammatory conditions including
AD. In line with those studies, we showed that single as well
as multiple low-dose infusion of HUCBC significantly
reduced amyloidogenic APP processing, Ab and b-amyloid
plaque accumulation, glial neuroinflammation, and cognitive impairments in preclinical AD mouse models11,12. Additionally, HUCBC treatment changed microglial phenotypes
from pro-inflammatory to anti-inflammatory, increased
microglial Ab phagocytosis, increased anti-inflammatory
cytokines in the brain (i.e., interleukin-10, transforming
growth factor b1, and nerve growth factor), and reduced
CD40 receptor-CD40 ligand (CD40-CD40L) interaction that
is important for Ab-induced pro-inflammatory microglial
activation13. To identify the specific HUCBC responsible
for this neuroprotective effect, we found that cord blood–
derived monocyte reduces b-amyloid pathology and
improves cognition with much more effectively than
monocyte-deficient cord blood in AD mouse model13. In line
with the findings of above studies, several recent reports
underscored the role of young blood and/or plasma in aging
and age-associated neurodegenerative conditions. Among
those, Wyss-Coray and other labs have reported that exposing old mice to a young systemic environment by parabiosis
increased synaptic plasticity, improved pathology, and behavioral recovery such as contextual fear conditioning and spatial learning in old mice. More interestingly, they also found
that it is not the blood cells rather the soluble factors that are
getting into the mice brain. They pooled plasma from young
mice as well as from young human and injected into old mice,
which successfully rejuvenated old mice brain structure and
cognition tested by Barnes maze memory test14–18. In a
follow-up study, they showed that human cord blood plasma
(CBP) as well as plasma enriched in tissue inhibitor of metalloproteinases 2 improves synaptic plasticity and hippocampaldependent cognitive function in old mice19.
Based on our preliminary laboratory findings, we
hypothesized that human cord blood serum (CBS) possesses
novel APP-specific a-secretase-like enzyme, reflected by
marked increase in sAPPa level. As CBS contains many
different small molecules, growth factors, proteins,
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inhibitors, hormones, enzymes, and other unknown substances, we also hypothesized that infusion of characterized
CBS fraction will ameliorate AD-like pathology and cognitive impairments in mouse models. Here, we show that CBS
markedly enhanced the level of sAPPa in Chinese hamster
ovary (CHO) cells stably expressing wild-type human APP
(CHO/APPwt cells) as well as mediated a-secretase cleavage of human neuron-specific APP695 (fAPP695) in a cellfree system, which effects are not seen with normal adult or
aged blood serum (ABS or AgBS). Additionally, we have
been successfully able to characterize a CBS fraction with
enhanced a-secretase-like catalytic activity (refer to aCBSF)
using sequential diethylaminoethanol (DEAE)-affinity column, size-exclusion, and anion-exchange chromatographic
fractionation processes. Moreover, we found that aCBSF
infusion increased sAPPa levels, decreased Ab production/
b-amyloid plaque formation, prevent neuronal loss and
abnormal tau (Thr231) phosphorylation in the cortex, and
improved cognitive function in Alzheimer’s mouse models.
Our findings indicate that aCBSF holds immense therapeutic
potential for treatment of AD.

Materials and Methods
Reagents and Antibodies
CBS was obtained from Lee Biosolutions (St. Louis, MO,
USA, and human umbilical CBP was obtained from STEMCELL Technologies Inc. (Vancouver, British Columbia,
Canada). Human cord blood is aspirated from the umbilical
cord vein into a cord blood collection bag containing citrate–
phosphate–dextrose as an anticoagulant. Individual lot of
CBP is prepared from a single cord blood sample. Three to
five different lots of CBP samples were pooled in as “pooled
CBP.” CBP is separated from umbilical cord blood centrifugation at 3,500 rpm for 5 to 10 min. CBP is aliquoted and
frozen at 20  C first and then transferred to a 80  C
freezer after 24 h at 4  C. There is no placement into 80

C for a snap freeze. Frozen CBP is not heat inactivated. No
analysis was performed to determine the number of platelets
in each sample; therefore, the plasma cannot be specifically
characterized as “low-platelet” or “platelet-poor” plasma.
Frozen CBP samples were thawed in a 37  C water bath
before being used in experiment. CBS was collected from
umbilical cord blood; and it is the blood that remains in the
placenta and in the attached umbilical cord after the cord has
been detached from the newborn at the time of childbirth.
CBS is separated from umbilical cord blood by allowing it to
clot for 5 to 10 h in red top tubes with no anticoagulation
followed by centrifugation at 3,500 rpm for 5 to 10 min at 4

C. CBS sample was passed through a filter membrane with
a pore size of 0.22 mm. Individual CBS was prepared from a
single sample. More than 10 serum samples of CBS were
pooled in as “pooled CBS.” Normal human adult blood
serum (ABS, 25 to 30 years old) and AgBS (>75 years old)
as well as their plasma (ABP and AgBP, respectively) were
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obtained from Florida Blood Services (Tampa, FL, USA).
Antibodies include specific anti-sAPPa monoclonal antibody (2B3; IBL, Minneapolis, MN, USA, Cat# 11088 RRID:
AB_494690), anti-APP C-terminal polyclonal antibody
(pAb751/770; EMD Millipore, La Jolla, CA, USA, Cat#
171610, RRID: AB_211444), anti-APP N-terminal monoclonal antibody (22C11; Merck Millipore, Billerica, MA,
USA, Cat# MAB348B, RRID: AB_11204540), anti-Nterminal Ab monoclonal antibody (6E10; Covance Research
Products, Emeryville, CA, USA), anti-Ab16–26 monoclonal
antibody (4G8; Covance Research Products, Cat# SIG-39200,
RRID: AB_10175149), anti-phospho-tau antibody (Thr231;
Merck Millipore, Billerica, MA, USA, Cat# AB9668, RRID:
AB_570891), anti-DDK-tagged antibody (Cell Signaling
Technology, Danvers, MA, USA, Cat# 2908, RRID:
AB_1905079), anti-NeuN antibody (Merck Millipore, Billerica, MA, USA, Cat# ABN90, RRID: AB_11205592), and
anti-b-actin monoclonal antibody (Sigma-Aldrich, St. Louis,
MO, USA, Cat# A5316, RRID: AB_476743). Human recombinant full-length APP695 (fAPP, 100 ng) tagged with Cterminal MYC/DDK was purchased from OriGene Technologies, Inc. (Rockville, MD, USA).

Cell Culture
CHO cell line with stable expression of human wild-type
APP (CHO/APPwt) was a generous gift from Drs. Stefanie
Hahn and Sascha Weggen (University of Heinrich Heine,
Düsseldorf, Germany). At the beginning of the experiment,
CHO/APPwt cells were genotyped and confirmed the
genetic makeup. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS), 1 mM sodium pyruvate, and 100 U/mL of penicillin/
streptomycin. For treatment, the cells were plated in a 24-well
plate at 2  105 cells/well for overnight incubation, washed
and treated with CBS (0% to 10%), inact CBS (5%), ABS (0%
to 10%), AgBS (0% to 10%), or aCBSF (0% to 1%) in
DMEM. After treatment, supernatants were collected and the
cells were washed with ice-cold phosphate-buffered saline
(PBS) 3X and lysed with cell lysis buffer (20 mM Tris, pH
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mg/mL leupeptin, and 1 mM
phenylmethane sulfonyl fluoride; Cell Signaling Technology,
Danvers, MA, USA). Both cell supernatants and lysates were
used for sAPPa analysis by ELISA. For immunoprecipitation,
100 ng of fAPP695 was incubated with aCBSF at 37  C for 1
h, and then the sAPPa/aCBSF-derived immune complex was
immunoprecipitated using 2B3 sAPPa-specific antibody or
anti-DDK antibody. The supernatants were then collected and
used for treatment of CHO/APPwt cells.

Cell-free a-secretase Assay
In order to determine the a-secretase activity of CBS
reflected by sAPPa level, human recombinant fAPP 695
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tagged with C-terminal MYC/DDK (100 ng; OriGen Biomedical, Austin, TX, USA) was incubated with CBS, heat inactivated CBS (inact CBS, 56  C for 30 min), AgBS, FBS, or
aCBSF at 37  C for 5 h in the presence or absence of protease inhibitor (PI) cocktail (1X; Sigma-Aldrich, St. Louis,
MO, USA), tumor necrosis factor-a (TNFa) converting
enzyme (TACE) inhibitor (TAPI-0) (1 mM; Abcam, Cambridge, MA, USA), or a disintegrin and metalloproteinase
domain–containing protein (ADAM) inhibitor (GM6001, 1
mM; Sigma-Aldrich, St. Louis, MO, USA). The reaction
mixtures were then subjected to Western blot (WB) analysis
for APP a-secretase processing. In addition, TACE and
ADAM10 cleavage activity of aCBSF was determined using
TACE (AnaSpec, Fremont, CA, USA) and ADAM10 cleavage activity kits (AnaSpec, Fremont, CA, USA), according
to the manufacturer’s instructions.

CBS Fractionation
Next, in order to purify and characterize the a-secretase in
CBS or AgBS, the Econo-Pac Serum IgG Purification Kit,
and 10DG columns (Bio-Rad, Philadelphia, PA, USA) were
initially employed to remove highly abundant IgG and salts.
The desalted serum was applied to DEAE Affi-Gel Blue
columns, and residual IgG was eluted according to the
instructions. Then, 20 additional protein fractions were collected by eluting with an ionic strength gradient of NaCl
buffer ranging from 0.1 M to 2.0 M. The remaining proteins
on the column were eluted by the regeneration buffer
included in the kit and collected as the regeneration fraction.
The 0.8 M NaCl-eluted protein fractions were combined
together and sent to Moffitt Cancer Center Protein Purification Core (Tampa, Fl, USA) for further separation by sizeexclusion chromatography, employing analytic Superdex
200 columns and eluting with PBS, and ion-exchange chromatography, employing Q-Sepharose columns and eluting
with 500 mM NaCl, 50 mM Tris, pH 7.6. The final enzyme
containing fractions was exchanged to PBS by Ultracel-10
membranes (10 kDa, Merck Millipore, Billerica, MA, USA)
for further experimentation and referred to as aCBSF or
AgBSF.

Animal Models
Both 5XFAD (MMRC Stock No: 34840-JAX; RRID
IMSR_JAX: 006554) and 3xTg-AD (MMRC Stock No:
34830-JAX) mice of male and female were purchased from
Jackson Laboratory (Bar Harbor, Maine, USA). In this preclinical study to investigate whether CBS fractionation
changes AD-like pathology and associated behavioral deficits, 5-month-old 5XFAD mice were used that harbor 5
mutations (APP KM670/671NL [Swedish], APP I716V
[Florida], APP V717I [London], PSEN1 M146L, and PSEN1
L286V)20 and rapidly develop AD-like pathology including
accumulation of high levels of extracellular b-amyloid plaques, neurodegeneration, and behavioral impairments. In
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order to investigate whether CBS fractionation administration changes both Ab and tau phosphorylation, 3xTg-AD
mice which harbor presenilin-1 (PS1/M146V), APP
(KM670/671NL), and tau (P301L) mutants were used. These
mice progressively develop b-amyloid and NFT pathology,
which potentially synergize to accelerate neurodegeneration
at the age of 6 months (6 mo)21. At the beginning of the
experiment, all mice were confirmed as mutant by polymerase chain reaction. One male and 4 female mice were housed
in a single cage separately. All animal experiments were
performed in accordance with the guidelines of the National
Institutes of Health and were approved by University of
South Florida (USF) Institutional Animal Care and Use
Committee (IACUC reference number: IS00000438). Transgenic mice used for aging studies may exhibit signs such as
ruffled hair coat, hair loss, excessive weight gain, and/or
loss. When one of these signs observed, mice were monitored more closely and weighed twice weekly. Mice exhibited multiple clinical signs or showing >20% weight loss
were excluded from the study. As per our previous practice,
if a mouse appears overtly sick or in pain as indicated by
ruffled, matted, or dull hair; hunched back or head pressing;
failure to move about the cage; failure to respond to stimuli,
rapid, shallow, labored breathing, twitching or trembling; or
failure to experience seizure, a veterinarian was consulted in
order to ensure timely intervention and treatment or removal
from the study. All mice were maintained on a 12-h light/
12-h dark cycle at ambient temperature and humidity and
housed in the Morsani College of Medicine Animal Facility
at the USF with ad libitum access to food and water.

Stereotaxic Intracerebroventricular (i.c.v.) Injection
In order to determine whether aCBS fraction could modify
Ab and tau pathology, cohorts of 17 (n ¼ 17, 9\/8_) triple
transgenic 3xTg-AD mice were arbitrary anesthetized with
isoflurane (2% to 3% induction, 1% maintenance). After
reflexes were checked to ensure that mice were unconscious,
they were positioned on a stereotaxic frame (Stoelting’s Lab
Standard™, Wood Dale, IL, USA) with ear bars positioned
and jaws fixed to a biting plate. The axis coordinates were
taken from a mouse brain atlas, and the needle of a Hamilton
microsyringe was implanted into the left lateral ventricle
delimited from the stereotaxic coordinates (coordinates relative to bregma: 0.6 mm anterior/posterior, þ1.2 mm medial/lateral, and 3.0 mm dorsal/ventral) using the stereotaxic
device. aCBSF (0.5 mg/mouse, n ¼ 6, 3\/3_), AgBSF (0.5
mg/mouse, n ¼ 6, 3\/3_), and PBS (1 mL/mouse, n ¼ 5, 3\/
2_) were administered at 1 mL/min. After administration, the
syringe was removed slowly to prevent bleeding and further
brain damage. The lesions were closed with 1 to 2 staples
and observed until anesthesia had cleared. Seventy-two hour
after the i.c.v. injections, animals were killed with isoflurane, then transcardially perfused with ice-cold PBS, and
brains were harvested for biochemical, histochemical, and
immunohistochemical analyses.
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Intraperitoneal (i.p.) Administration With an Osmotic
Mini Pump
Mice were labeled using tail tattooing by veterinarian who
was blinded about the entire experiment. In order to
determine whether CBS fractionation changes AD-like
pathology and associated behavioral deficits, cohort of
even-number labeled 5XFAD mice was randomly assigned
to 2 experimental groups of 6 mice each, receiving aCBSF
(n ¼ 6, 3\/3_) or AgBSF (n ¼ 6, 3\/3_) treatment by an
Alzet® osmotic mini pump (Alzet 2004, DURECT Corporation, Cupertino, CA, USA). A third group of wild-type
(WT) control mice received aCBSF (n ¼ 6) through the
same administration route. Mice were briefly anesthetized
with isoflurane as described previously, an area of the
abdomen was shaved, a 1-cm abdominal incision was made
and an Alzet® osmotic mini pump was filled with 100 mL of
CBSF, or AgBSF was implanted i.p.. The pump delivered
these fractionated sera at a constant rate of 0.15 mL/h for
6 wk, yielding a treatment dose of 1 mg/kg/day or 30 mg/
mouse/day. At the end of 4- to 5-weeks (wk) treatment
(6 mo of age), cognitive evaluations were conducted in
these mice with our established behavioral battery. After
6 wk treatment, mice were killed with isoflurane, then
transcardially perfused with ice-cold PBS, and brains were
removed to assess b-amyloid plaque pathology.

Behavioral Assessments
Novel object recognition test. Novel object recognition is
based on the spontaneous tendency of a mouse to explore
a new object compared with an old object. At first, during
the habituation phase (day 1), each mouse was acclimatized
with the testing apparatus box for 10 min. Next, during the
training day (day 2), each mouse was familiarized with 2
similar objects (4 cm  4 cm  4 cm) for 10 min. Finally,
during the testing day (day 3), one of the objects was
replaced with a new object and tested for 10 min. The
amount of time spent exploring the new and old objects
during the test phase was quantified by video tracking
(ANY-Maze; Stoelting’s Lab Standard™, Wood Dale, IL,
USA) and provides an index of recognition memory. Discrimination index was calculated as the frequency of exploration of new versus original objects.
Y-maze test. Y-maze test was performed as described previously22. This task was used to assess basic mnemonic processing by spontaneous percentage alternation and
exploratory activity of mice placed into a black Y-maze. The
arms of this maze were 21-cm long and 4-cm wide with 40cm high walls. Each mouse was placed in one of the arms
and allowed one 5-min trial of free exploration of the 3 alleys
in the maze. The numbers of total arm choices and sequence
of arm choices were recorded.
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Histochemical and Immunohistochemical Analyses
Mice were euthanized with isoflurane and then transcardially perfused with ice-cold PBS. Brains were rapidly isolated, and one hemisphere was frozen immediately in liquid
nitrogen and stored at 80  C. For molecular analysis, brain
hemispheres were sonicated in radioimmunoprecipitation
assay buffer (Cell Signaling Technology, Danvers, MA,
USA), centrifuged at 14,000 rpm for 1 h at 4  C, and supernatants were isolated for WB analyses. The other hemisphere
was placed in 4% paraformaldehyde for cryostat sectioning.
The 25-mm free-floating coronal sections were collected and
stored in PBS with 100 mM sodium azide at 4  C. Immunohistochemical staining was performed using various primary
antibodies in conjunction with the VECTASTAIN Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA)
coupled with diaminobenzidine substrate. A set of sections
without adding primary antibody were used as negative
staining control. Sections were also stained with Congo red
dye and Thioflavin-S fluorescence dye for detecting fibrillary Ab species as described previously23,24. Images of five
25-mm sections (150 mm apart) through hippocampus and
neocortex were captured, and a threshold optical density was
obtained that discriminated staining from background. Data
are reported as percentage of immunolabeled area captured
(positive pixels divided by total pixels captured). Quantitative image analysis was performed by a single examiner
(T.M.) blinded to sample identities.

WB Analysis and ELISA
WB analyses and quantification were performed as previously described25. Briefly, the proteins from the cell-free
suspensions, cell lysates, and homogenized tissue were electrophoretically separated using 10% bicine/Tris gel (8 M
urea) for proteins less than 5 kDa or 10% Tris/sodium dodecyl sulfate (SDS) gels for larger proteins. Electrophoresed
proteins were transferred to nitrocellulose membranes (BioRad), washed, and blocked for 1 h at room temperature in
Tris-buffered saline containing 5% (w/v) nonfat dry milk
(TBS/NFDM). After blocking, membranes were hybridized
overnight with various primary antibodies, washed, and
incubated for 1 h with the appropriate horseradish
peroxidase-conjugated secondary antibody in TBS/NFDM.
Blots were developed using the luminol reagent (Thermo
Fisher Scientific, Waltham, MA, USA). The sAPPa ELISA
(IBL) was performed according to manufacturer’s
instruction.

Statistical Analysis
Comparison between 2 groups were performed by Student’s
t-test analysis. For more than 2 groups, one-way analysis of
variance followed by Least Significance Difference (LSD)
post hoc analysis was used to compare each other for statistical significance. The a was set at p < 0.05 for all analyses.
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The significance level of P value was set at < 0.05 for all
analyses. All the mice experiment were repeated 3 times in
parallel to attain the above significant difference. Data are
expressed as mean + standard error of the mean. The statistical package for the social sciences released by IBM
SPSS Version 23.0 (IBM, Armonk, NY, USA) was used for
all data analyses.

Results
CBS Dose-Dependently Promotes a-cleavage in
CHO/APPwt Cells
Our previous studies indicate that both single and multiple
low-dose infusions of HUCBC as well as HUCBC-derived
monocytes can significantly reduce b-amyloid plaques and
cognitive impairments in AD mouse models. Having shown
that HUCBC can reduce AD pathology, we next set out to
determine whether human umbilical–derived CBS could
also reduce b-amyloid pathology through alteration of APP
processing. CHO/APPwt cells were treated with different
concentrations (0% to 10%, 6 different doses) of CBS, ABS,
or AgBS for 4 h (Fig. 1A and B, left panel). The conditioned
media were collected and subjected to sAPPa ELISA, and
also sAPPa WB analysis using 2B3 sAPPa-specific antibody. CBS dose-dependently promoted sAPPa levels with
greater than that elicited by ABS and AgBS. Similarly,
CHO/APPwt cells were treated with 5% CBS, ABS, or
AgBS for 6 different time points (0 to 4 h, Fig. 1A and B,
right panel). CBS time-dependently promoted sAPPa levels
with greater than that elicited by ABS and AgBS. To see
whether the factor present in the serum mediating a-secretase activity is proteinaceous in nature, we treated CHO/
APPwt cells with heat inactivated serum (inact CBS) for 4
h. As expected, heat inactivation limited the sAPPa producing capacity of CBS, as shown by ELISA (Fig. 1C, upper
panel) and WB (Fig. 1C, lower panel). Therefore, CBS possesses a-secretase, reflecting sAPPa level in a dose- and
time-dependent fashion and the factor mediating this activity
is heat-labile and most likely a protein. These results indicate
that FBS also contains a heat sensitive a-secretase.

CBS Mediates a-Cleavage of Neuron-specific APP695
Independent of ADAM Activity
Next, we tested whether the a-secretase in CBS is mediated
by TACE (ADAM17) or ADAM. Human recombinant
fAPP695 (100 ng)-tagged with C-terminal MYC/DDK was
incubated with CBS, inactivated CBS (inact CBS), or AgBS
at 37  C for 5 h in the presence or absence of different inhibitors (PI cocktail [1X], TAPI-0 [1 mM], or ADAM inhibitor
[GM6001, 1 mM]; Fig. 2A). The reaction mixtures were subjected to sAPPa WB analysis using 2B3 sAPPa-specific antibody (Fig. 2A, upper panel) and total APP analysis using
6E10 anti-Ab1-17 antibody (Fig. 2A, lower panel). PI cocktail
significantly limited CBS-derived a-secretase catalytic
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Fig. 1. Cord blood serum (CBS), but not adult blood serum (ABS) or aged blood serum (AgBS), markedly promotes amyloid precursor
protein (APP) a-cleavage in a time-, dose-, and temperature-dependent manner. (A) Chinese hamster ovary cells stably expressing wild-type
human APP (CHO/APPwt) cells were treated with 0, 0.25, 0.5, 1, 5, and 10% CBS, ABS, or AgBS (left panel). In addition, CHO/APPwt cells
were treated with 5% CBS, ABS, or AgBS between 0 h and 4 h as indicated (right panel). (B) CHO/APPwt cells were treated with CBS at
different concentration (0% to 10%) for 4 h (left panel) or treated with 5% CBS for different time point (0 to 4 h), as indicated (right panel).
Conditioned media were subjected to soluble amyloid precursor protein a (sAPPa) ELISA (Fig. 1A and B, top panel) and Western blot (WB)
analyses (Fig. 1B, bottom panel) with 2B3 antibody (C) CHO/APPwt cells treated with heat inactivated serum (inact CBS) or CBS for 4 h.
Conditioned media were subjected to sAPPa ELISA (Fig. 1C, top panel) and WB analyses (Fig. 1C, bottom panel) with 2B3 antibody. Data are
presented as mean (+SD) of sAPPa produced (ng/mg or ng/mL) from 5 independent experiments in triplication. Human umbilical cord
blood plasma (CBP) produced similar results (data not shown). APP a-secretase activity of pooled CBS or CBP or individualized CBS or CBP
was similar (data not shown).

activity, as reflected by sAPP695 level, but this activity was
not limited by TACE or ADAM inhibitors (Fig. 2A, upper
panel). In addition, fAPP695 (100 ng) was incubated with 5%
CBS, FBS, or inactivated CBS for 1, 5, or 24 h. CBS
a-secretase increased the level of sAPP 695 in a timedependent manner, measured by 2B3 antibody (Fig. 2B, upper
panel). As shown, the level of sAPP770 represents endogenous
sAPPa.

Removal of High- and Low-abundance Proteins
Increases Activity of CBS a-secretase
To purify and ultimately identify the target protein/complex
mediating CBS a-secretase catalytic cleavage, 3-step chromatographic separation techniques were employed. Initially,
removal of highly abundant immunoglobulins and desalting

were performed using Bio-Rad Econo-Pac Serum IgG Purification Kit and 10DG columns. Desalted CBS was then
applied to DEAE Affi-Gel Blue columns to completely
remove IgGs and collect 20 additional protein fractions and
eluted with increasing strengths of NaCl buffer. CHO/
APPwt cells were treated with each fraction for 2 h to determine a-secretase by ELISA. In addition, unfractionated
whole and desalted CBS positive control as well as PBSnegative control was used to treat cells. These sequential
approaches significantly increased a-secretase, with the fractions showing the highest a-secretase catalytic activity, as
reflected by sAPPa level eluting around 0.6 to 0.9 M NaCl
concentrations (Fig. 3A). As shown in Fig. 3C, 0.7 to 0.9 M
NaCl fractions from 10 CBS lots increased sAPPa levels at
least with maximum 5-fold higher than whole CBS. In addition, the fractionated and whole CBS was run in SDS-
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Fig. 2. Cord blood serum (CBS) directly mediates a-cleavage of neuron-specific amyloid precursor protein (APP695), but this activity is not
mediated by a disintegrin and metalloproteinase domain-containing protein (ADAM) and tumor necrosis factor-a converting enzyme
(TACE). (A) Human recombinant full-length APP695 tagged with C-terminal MYC/DDK (fAPP695, OriGen, 100 ng) was incubated with
5% CBS, inact CBS, or aged blood serum (AgBS) at 37  C for 5 h in the presence or absence of a protease inhibitor cocktail (PI, 1 X), TACE
(ADAM17) inhibitor (TAPI-0, 1 mM), or ADAM inhibitor (GM6001, 1 mM). Lanes 1 to 4 represent CBS (1), inact CBS (2), AgBS (3), and fetal
bovine serum (FBS; 4) sample only control without substrate fAPP695. Lane 5 represents fAPP695 (5) substrate only control without any
serum sample. Lanes 6 to 11 represent substrate fAPP695 with CBS (6), inact CBS (7), CBS with PI (8), CBS with TAPI-0 (9), CBS with
GM6001 (10), and AgBS (11). Lanes 12 to 14 represent (lanes 12 to 14; PI (12), TAPI-0 (13), and GM6001 (14) inhibitor and substrate
control, respectively, without any serum sample. The reaction mixtures were subjected to soluble amyloid precursor protein a (sAPPa)
Western blot (WB) analysis using 2B3 antibody (top panel) and total APP using 6E10 (an anti-Ab1-17 antibody; lower panel). sAPP770 refers to
the endogenous a-secretase cleavage product of CBS or AgBS, whereas sAPP695 refers to the a-secretase cleavage product of fAPP695. (B)
100 ng of fAPP695 was incubated with 5% CBS for 1, 5, or 24 h, or 5% FBS or inact. FBS for 24 h, and then subjected to sAPPa and total APP
WB analysis using 2B3 (top panel) and 6E10 (lower panel), respectively. sAPP770 refers to the endogenous a-secretase cleavage product of
CBS or AgBS, whereas sAPP695 refers to the a-secretase cleavage product of fAPP695.

polyacrylamide gel electrophoresis (PAGE), demonstrating
numerous proteins remaining in each CBS fraction (Fig. 3C,
right upper panel). Therefore, we selected the 0.8 M NaCleluted fraction for further purification. As shown in Fig. 3B,
the level of total protein concentration is represented in mg/
mL in CBS fraction.

Further Purification of CBS a-Secretase Using
Size-exclusion and Anion-exchange Chromatography
The 0.8 M NaCl-eluted fraction of CBS was subjected to
size-exclusion chromatography using Superdex 200 prep
grade columns (XK 16/40, GE Healthcare, PA, USA) packed
with cross-linked agarose and dextran. The mobile phase
was 20 mg/mL acetone in distilled water, and the detection
was performed at UV280 nm. Approximately 100 mg of
protein from the 0.8 M NaCl fraction was applied to the
column, and 48 fractions were eluted with PBS. The catalytic activity of a-secretase was greatly enhanced, as tested on
CHO/APPwt cells by measuring sAPPa production. Fractions #11 and 12 produced sAPPa > 5-fold higher compared
with the original 0.8 M NaCl-eluted fraction as well as all
other fractions, as determined by WB (upper panel) and

ELISA (Fig. 4A, lower panel). To confirm the enhancement
of a-secretase, we determined the sAPPa in fractions #8 to
18 along with the original 0.8 M NaCl-eluted fraction from 3
different CBS lots. Fractions #10 to 13 showed a-secretase
activity 15-fold more than the original 0.8 M NaCl-eluted
fraction, as measured by ELISA (Fig. 4C). As determined by
SDS-PAGE, the molecular mass of the #10 to 13 fractions
was 177 to 275 kDa (Fig. 4C).
To examine the charge of a-secretase protein/complex in
CBS, the size-exclusion fractions containing the highest
a-secretase catalytic activities, as reflected by sAPPa levels
(#10 to 13), were further subjected to anion-exchange chromatography using Q-Sepharose columns. Proteins from the
size-exclusion fractions were applied to the column and 82
fractions were eluted with 0.5 M NaCl. Fractions #53 to 56
showed > 8-fold higher a-secretase catalytic activity, as
reflected by sAPPa level than the original size-exclusion
fraction, as determined in CHO/APPwt cells by WB and
ELISA (fractions #2 to 4 in Fig. 5A, upper and lower panels,
respectively). To further compare the enzymatic activity of
CBS samples before and after anion-exchange chromatography, we collected fractions #1 to 5 and #23 from 3 different
samples and determined the sAPPa level in each indirect
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aCBSF Promotes Nonamyloidogenic APP Processing
Human recombinant fAPP695 was incubated with 5 different
concentrations (0% to 1%) of aCBSF at 37  C for 2 h. The
reaction mixtures were subjected to sAPPa WB analysis
using 2B3 antibody as well as fAPP and a-CTF analyses
using pAPP751/770 antibody (an anti-APP C-terminal antibody; Fig. 6A). This analysis showed that aCBSF increases
sAPPa as well as a-CTF fragments and decreases (fulllength) holo APP with increasing doses.
In order to confirm that aCBSF mediates novel a-secretase
independent of TACE or ADAM, fAPP695 was incubated with
aCBSF in the absence or presence of ADAM (GM6001, 1 mM)
or TAPI-0 (1 mM) for 1 h. aCBSF treatment alone increased the
levels of APP-processing fragments such as sAPPa and a-CTF
and decreased the level of holo APP as determined by WB,
whose effects did not alter significantly by GM6001 and TAPI0 combined treatment with aCBSF (Fig. 6B). In addition,
TACE and ADAM10 enzymatic activities of aCBSF were
measured by TACE and ADAM10 cleavage activity kits.
TACE (25 mg/mL) in the presence or absence of TAPI-0 (1
mM) and ADAM10 (50 mg/mL) in the presence or absence of
ADAM inhibitor (GM6001, 1 mM) were included as positive
controls. Results suggest that aCBSF has very little TACE or
ADAM10 activity (Fig. 6C and D).
Fig. 3. Fractionation of amyloid precursor protein (APP)-specific
a-secretase activity in cord blood serum (CBS). To purify and
eventually identify the a-secretase activity in CBS, the Econo-Pac
Serum IgG Purification Kit (Bio-Rad, Philadelphia, PA, USA) was
initially employed to remove highly abundant IgG. CBS was then
desalted using Econo-Pac 10DG columns. The desalted serum was
applied to DEAE Affi-Gel Blue columns to remove residual IgG and
collect 20 additional protein fractions, by eluting with an increasing
ionic strength gradient of NaCl buffer ranging from 0.1 M to 2.0 M.
The remaining proteins on the column were eluted by the regeneration buffer included in the kit and collected as the regeneration
fraction (Reg). (A) Chinese hamster ovary cells stably expressing
wild-type human APP (CHO/APPwt) cells were cultured in 24-well
plates and treated with 10 mL of each protein fraction for 2 h.
Conditioned media were then collected and analyzed by soluble
amyloid precursor protein a (sAPPa) Western blot (upper panel)
and ELISA (lower panel). 10 mL CBS, desalted CBS, and phosphatebuffered saline (PBS; Ctrl) were included under the same cell culture conditions as positive and negative controls, respectively. Cell
lysates were also prepared from each fraction-treated cell culture
as an additional reference to evaluate sAPPa production levels (data
not shown). (B) Protein concentration of each fraction. (C) CHO/
APPwt cells were treated with the 0.6 to 1.0 M NaCl-eluted fractions
from 10 different CBS lots, as well as whole CBS and PBS (Ctrl), for 2
h and the conditioned media were collected for sAPPa ELISA. The
results were presented as mean (+SD) sAPPa produced (ng/mg
protein). In addition, each protein fraction was subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis to assess total
protein fractionation (C, right panel).

measurement of CBS a-secretase activity. Combined fractions #2 to 4 produced sAPPa > 50-fold higher than the
original eluted (#23) fraction, as measured by ELISA (Fig.
5C). Combined fractions #2 to 4, referred to hereafter as
aCBSF, were therefore used for further analysis.

Immunoprecipitation of fAPP695/CBS Specifically Limits
APP a-secretase Cleavage
To determine whether immunoprecipitation could specifically
limit a-secretase of aCBSF, 100 ng of fAPP695 was incubated
with 0.125 mg of aCBSF at 37  C for 1 h, and the sAPPa/
aCBSF immune complex was immunoprecipitated using antiDDK antibody, 2B3, or nonspecific IgG. CHO/APPwt cells
were treated in the FBS free condition for 2 h with the supernatants collected from the immune complex or PBS as reference control, and then conditioned media were analyzed by
sAPPa WB using anti-N-terminal APP antibody (22C11; Fig.
7A) and sAPPa ELISA (Fig. 7B) to determine a-secretase in
CBS. Immunoprecipitation of the sAPPa/aCBSF with antiDDK antibody significantly reduced a-secretase activity of
aCBSF, indicating that immunoprecipitation limits the
CBS-mediated APP a-secretase cleavage. In contrast, immunoprecipitation of sAPPa/aCBSF with 2B3 did not reduce
CBS a-secretase, indicating that aCBSF does not form an
immune complex with sAPPa. In addition, there was no notable or significant difference in sAPPa production elicited by
0.5% supernatant from aCBSF IP with control IgG and 2.5%
(equivalent to 0.5% Super) aCBSF alone (data not shown).

aCBSF Reduces b-cleavage, Promotes a-cleavage
of APP, and Stabilizes Tau Phosphorylation in
3xTg-AD Mice
To test whether aCBSF suppresses b-site APP-cleaving
enzyme 1 (BACE1)-mediated APP processing in vivo,
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Fig. 4. Protein size-exclusion chromatography by preparative-grade Superdex 200 column. The 0.8 M NaCl-eluted protein fraction of cord
blood serum was further subjected to size-exclusion chromatography by analytic Superdex 200 column. Approximately 100 mg of protein
from the 0.8 M NaCl fraction was applied to the column, and 48 fractions were eluted with phosphate-buffered saline (PBS). (A) Chinese
hamster ovary cells stably expressing wild-type human APP (CHO/APPwt) cells were cultured in 24-well plates and treated with 40 mL of
each protein fraction for 2 h. The conditioned media were collected and analyzed by soluble amyloid precursor protein a (sAPPa) Western
blot (upper panel) and ELISA (lower panel). In parallel, the 0.8 M NaCl-eluted fraction (#31) and PBS (#32) were included under the same cell
culture conditions as positive and negative controls, respectively. Cell lysates were also prepared from each fraction-treated cell culture as
an additional reference to evaluate sAPPa levels. (B) Protein concentration of each size fraction. (C) CHO/APPwt cells were treated with #8
to 18 size fractions prepared from 3 independent experiments, as well as the original 0.8 M NaCl fraction (#31) and PBS (#32), and then
conditioned media were collected and analyzed by sAPPa ELISA. The results were presented as mean (+SD) sAPPa produced (ng/mg
protein). In addition, each size fraction was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis to assess total
protein fractionation (C, right panel).

4-mo-old 3xTg-AD mice were treated aCBSF, AgBSF (0.5
mg/mouse), or PBS control (1 mL/mouse) with i.c.v. injections. After 72 h of treatment, in homogenates prepared from
the right hemisphere (noninjection side), WB analysis using
Ab1-17 antibody (6E10) shows that aCBSF reduced Ab (Fig.
8A) and b-CTF production (Fig. 8C), whereas enhancing
sAPPa production (Fig. 8B) compared with AgBSF and
PBS control. Compared with AgBSF and PBS, aCBSF
also reduced tau (Thr231) phosphorylation in these mice
(Fig. 8D).

decreases cortical and hippocampal b-amyloid plaques (Fig.
9A, upper panel) and reduces fibrillary Ab species visualized
by Thioflavin-S histochemical staining (Fig. 9A, lower
panel) compared with AgBSF treatment. Moreover, the
aCBSF-treated cohort also revealed less b-amyloid plaque
pathology than the AgBSF-treated cohort, as determined by
Congo red histochemical staining (Fig. 9A, middle panel).
Quantitative analysis disclosed that aCBSF therapy significantly ameliorated b-amyloid pathology, as determined by
4G8 antibody staining in both neocortex and hippocampus
regions compared with AgBSF treatment (Fig. 9B).

aCBSF Ameliorates b-amyloid Pathology in
5XFAD Mice

Neuroprotective Effects of aCBSF

To determine the effect of aCBSF on b-amyloid pathology,
transgenic 5XFAD mice at the age of 5-month-old were
continuously treated with aCBSF or AgBSF via i.p. osmotic
mini pump for 6 wk. Immunohistochemical staining using
4G8 antibody showed that aCBSF treatment substantially

5XFAD mice undergo neuronal loss in the neocortex and
hippocampus that is associated with behavioral deficits.
We examined whether continuous delivery of aCBSF by
i.p. osmotic mini pump can elicit a neuroprotective effect
in 5XFAD mice. Treatment with aCBSF partially prevented
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Fig. 5. Further fractionation by anion-exchange chromatography. The size-exclusion fractions containing the highest amyloid precursor
protein (APP) a-secretase activities (#10 to 13) were further subjected to anion-exchange chromatography using Q-Sepharose columns.
Approximately 10 mg of protein from the size-exclusion fraction(s) was applied to the column, and 82 fractions were eluted with buffer
containing 50 mM Tris, 500 mM NaCl, pH 7.6. (A) Chinese hamster ovary cells stably expressing wild-type human APP (CHO/APPwt) cells
were treated with 40 mL of each protein fraction for 2 h and conditioned media and cell lysates were analyzed by soluble amyloid precursor
protein a (sAPPa) Western blot (upper panel) and ELISA (lower panel). The original size exclusion–eluted fraction (#23) and phosphatebuffered saline (#24) were included as positive and negative controls respectively. In addition, sodium dodecyl sulfate polyacrylamide gel
electrophoresis of #2 to 4 anion-exchange fractions showed the presence of multiple proteins (middle panel). (B) Protein concentration of
each fraction. (C) CHO/APPwt cells were treated with the #1 to 4 anion-exchange fractions prepared from 3 independent experiments, and
then conditioned media were subjected to sAPPa ELISA. The results are presented as mean (+SD) of sAPPa produced (ng/mg protein). The
original size exclusion–eluted fraction (#23) was included as a positive control. Combined fractions #2 to 4, referred to as aCBSF, were used
for further analysis.

neuronal loss in the neocortex region compared with AgBSF
treatment, as demonstrated by NeuN antibody immunohistochemical staining, thus indicating that aCBSF may confer
neuroprotective ability for AD brain (Fig. 10A and B).

aCBSF Improves Learning, Memory, and Cognitive
Function in 5XFAD Mice
5XFAD mice received continuous treatment with aCBSF or
AgBSF via i.p. osmotic mini pump for 6 wk and evaluated
for cognitive function by novel object recognition and Ymaze tests during 4-5 wk of treatment. Novel object recognition test showed that aCBSF-treated 5XFAD mice spent
more time with the novel versus old objects, whereas
AgBSF-treated 5XFAD mice spent the same period of time
with both novel and old objects (Fig. 11A). Thus, discrimination index (%) was enhanced by aCBSF compared with
AgBSF treatment (Fig. 11B). Notably, improvement was

complete because there was no significant difference (P >
0.05) from WT control mice (NTg). In addition, aCBSF
treatment significantly increased the number of entries (Fig.
11C) and spontaneous alterations in 5XFAD mice compared
with the AgBSF-treated cohort (Fig. 11D), as determined by
Y-maze test, thus confirming that aCBSF treatment improved
learning and working memory in this AD mouse model.

Discussion
Recent progress in HUCBC therapy for different neurological diseases 26,27 opened new opportunities for AD
research 28 . We have previously found that multiple
low-dose peripheral infusion of HUCBC reduced cerebral
b-amyloid plaques, cerebral amyloid angiopathy, and astrocytosis, whereas these treatments improved cognitive
impairments in the PSAPP AD mouse model11 and enhanced
neurogenesis in the aged rat brain29. In a subsequent study,
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Fig. 6. Cord blood serum–specific fraction with enhanced a-secretase catalytic activity (aCBSF) directly mediates a-cleavage of neuronspecific amyloid precursor protein (APP695), but this activity is not mediated by a disintegrin and metalloproteinase domain–containing
protein (ADAM) or tumor necrosis factor-a converting enzyme (TACE). (A) Human recombinant full-length APP695 (fAPP695, 100 ng) was
incubated with 0, 0.125, 0.25, 0.5, or 1 mg of aCBSF at 37  C for 2 h. The reaction mixtures were subjected to soluble amyloid precursor
protein a (sAPPa) Western blot (WB) analysis using 2B3 (top panel) and holo APP and a-C-terminal fragment (a-CTF) analysis using
pAPP751/770 antibody (lower panel). (B) fAPP695 (100 ng) was incubated with 0.125 mg of aCBSF in the absence or presence of ADAM
(GM6001, 1 mM) or TACE inhibitor (TAPI-0, 1 mM) for 1 h and then subjected to sAPPa, holo APP, and a-CTF WB analysis using 2B3 (top
panel) and pAPP751/770 (lower panel). a-CTF of APP was further confirmed by an additional WB using an antibody specifically against Ab1726 (4G8). In addition, incubating human recombinant fAPP751 with aCBSF produces similar results (data not shown). (C) The tumor necrosis
factor-a converting enzyme (TACE or ADAM17) activity of aCBSF was measured by TACE cleavage activity kit. TACE (25 mg/mL) secretase
in the presence or absence of TACE inhibitor (TAPI-0, 1 mM) was included as positive control. (D) In parallel, the ADAM10 activity of the
aCBSF was measured by ADAM10 cleavage activity kit. ADAM10 (50 mg/mL) secretase, in the presence or absence of ADAM inhibitor
(GM6001, 1 mM), was included as positive control. TACE (ADAM17), and ADAM10 cleavage activities were determined for 1 h and
expressed as relative fluorescence units. These results are presented as mean (+SD) of 3 independent experiments with triplicates for each
condition.

we have reported that HUCBC-derived monocytes reduced
cerebral b-amyloid pathology and cognitive impairments13.
In addition, we have revealed that HUCBC-derived monocyte more effectively removed Ab by phagocytosis than the
aged monocyte, whereas sAPPa enhanced Ab phagocytosis
by the aged monocyte by forming a complex with Ab via the
help of monocyte scavenger receptor13. In support of these
findings, we demonstrated that overexpression of sAPPa
significantly reduces both cerebral b-amyloid6 and tau
pathology in crossing Tg-sAPPa with PSAPP mice7. Meanwhile, using a sophisticated parabiosis mouse model, WyssCoray and colleagues showed that blood serum from old
mice reduces neurogenesis and impairs cognitive functions
when administered into young mice30. Subsequently, several

groups reversed age-related cognitive impairments in aged
mice by infusing plasma from young into old mice14–16 as
well as AD pathology18. More specifically, Wyss-Coray
group have published several articles over the last few
years14,19, showing the potential of young and/or umbilical
cord plasma in ameliorating aged-associated cognitive
impairments. In those experiments, they have either joined
the young and aged mice through parabiosis or injected
young and/or umbilical cord blood–derived plasma into aged
mice via tail vein injection. Interestingly, only 3 to 4 injections within 3- to 4-wk period of time improved cognitive
impairments in those experiments. These results encouraged
us to determine whether human CBS could effectively
reduce AD pathology in vitro (i.e., cell culture and
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Fig. 7. Immunoprecipitation of full-length amyloid precursor protein (APP695)/cord blood serum–specific fraction with enhanced
a-secretase catalytic activity (aCBSF) specifically limits APP asecretase activity of aCBSF. To determine whether immunoprecipitation could limit the ability of aCBSF to promote APP a-cleavage,
we incubated 100 ng of fAPP695 with 0.125 mg of aCBSF at 4  C for
overnight and then immunoprecipitated (IP) the soluble amyloid
precursor protein a (sAPPa)/aCBSF immune complex using an
anti-DDK antibody (DDKAb), an sAPPa-specific antibody (2B3),
or nonspecific IgG. Chinese hamster ovary cells stably expressing
wild-type human APP cells were treated with the supernatants
(Super.) from each immune complex, or phosphate-buffered saline
as control, in the fetal bovine serum–free condition. Two hours
after treatment, conditioned media were collected and analyzed by
sAPPa Western blot (WB) using anti-N-terminal APP antibody
(22C11, A) and sAPPa ELISA (B). For Panel (B), the results were
presented as mean (+SD) of sAPPa production (ng/mL) in the
conditioned media from 3 independent experiments with triplicates
for each condition. There was no notable or significant difference in
sAPPa production elicited by 0.5% supernatant from aCBSF immunoprecipitated with control IgG (Ctrl) and 2.5% (equivalent to 0.5%
Super.) of aCBSF alone, as determined by sAPPa WB and ELISA
analysis (data not shown).

cell-free systems) as well as in vivo (i.e., 3xTg-AD and
5XFAD mouse models) by enhancing sAPPa production.
Our preliminary findings indicate that CBS possesses
a-secretase-like enzyme in cell culture and cell-free systems.
In CHO/APPwt cells, CBS produces greater amount of
sAPPa compared with ABS and AgBS in a concentrationand time-dependent manner (Fig. 1A and B). Since a-secretase is proteinaceous and heat-labile, we hypothesized that
a-secretase-like enzyme displayed by CBS is also inactivated by heat treatment. As expected, heat inactivation significantly limited the sAPPa-producing capacity of CBS
(Fig. 1C). These results suggest that a-secretase-like enzyme
of CBS is most likely a single complex protein that interacts
with and cleaves APP. Subsequent study indicated that CBS
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mediates a-secretase cleavage of neuron-specific APP695 in
a cell-free system, further suggesting that this activity is
mediated by an endogenous enzyme (Fig. 2A and B).
To purify, characterize, and ultimately identify this
a-secretase-like content in CBS, we employed 3-step affinity
column, size-exclusion, and anion-exchange chromatography techniques in a sequential manner (Fig. 3–5). These
sequential purification steps enhanced the catalytic activity
more than 3,000-fold compared with original CBS. The fractions containing highest a-secretase catalytic activity, as
reflected by sAPPa level, were combined and termed as
“aCBSF” for the further study. SDS-PAGE analysis of the
fractions from size-exclusion and anion-exchange chromatography yielding the highest a-secretase indicated size of our
unknown enzyme could be around 177 to 275 kDa (Figs. 4
and 5). It is not easy for a 177- to 275-kDa protein to cross
the blood–brain barrier through i.p. mini pump administration without any inhibition. We do not believe the protein is
larger than 275 kDa based on the markers in for our gels.
However, the SDS-PAGE also showed some low-molecularweight compounds that cannot be ruled out as well, which
warrant further investigation. Interestingly, TAPI
(ADAM17) and GM6001 (ADAM) inhibitors did not alter
a-secretase in CBS, indicating that the enzyme is not TACE
or ADAM, whereas the activity was dramatically reduced by
PI/cocktail, confirming that the activity is mediated by a
protease (Figs. 2 and 6). Moreover, immunoprecipitation
of aCBSF with 2B3 antibody (anti-C-terminal of sAPPa)
showed significant reduction in sAPPa levels, indicating that
a-secretase-like enzyme aCBSF physically interacts with
sAPPa (Fig. 7).
Previously, we and others have shown that sAPPa
reduces b-amyloid pathology via inhibition of BACE16. In
a recent article, we have shown that sAPPa decreases tau
phosphorylation via BACE1 inhibition and GSK-3bmediated inhibitory phosphorylation7. This study prompted
us to investigate the functional efficacy of fractionated CBS
(aCBSF) in 5XFAD and 3xTg-AD mouse models. We have
shown that aCBSF significantly reduced Ab and tau phosphorylation (p-tau-Thr 231 ) in 3xTg-AD mice, whereas
aCBSF enhanced a-secretase cleavage products (i.e., sAPPa
and a-CTF), indicating that a-secretase-like content in CBS
promotes APP nonamyloidogenic processing in vivo (Fig.
8B and C). In 5XFAD mice with aggressive b-amyloid
deposition and plaque formation, aCBSF reduced b-amyloid
plaque pathology in both neocortex and hippocampus
regions, and reduced neural loss in the neocortex region,
compared with AgBSF-treated mouse brains (Fig. 9 and
10). By carrying out sequential fractionation, we markedly
enhanced CBS-derived a-secretase (termed aCBSF) and
infused into 5XFAD mice via osmotic mini pump over the
period of 6 wk. Behavioral analyses in 5XFAD mice indicate
that aCBS-treated mice showed improved episodic memory,
as determined by novel object recognition test (Fig. 11A and
B), as well as spatial working memory, as determined by
Y-maze test (Fig. 11C and D), compared with AgBSF
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Fig. 8. Cord blood serum–specific fraction with enhanced a-secretase catalytic activity (aCBSF) promotes amyloid precursor protein (APP)
a-secretase processing in vivo. 3xTg-AD female mice at 4 mo of age were treated with aCBSF, aged blood serum fraction with enhanced asecretase activity (0.5 mg/mouse; n ¼ 6), or phosphate-buffered saline control (1 mL/mouse; n ¼ 5 female) by i.c.v. injection and euthanized 72
h later. Mouse brain homogenates were then prepared from the right half of the brain (noninjection side). (A) Western blot (WB) analysis
using Ab1-17 antibody (6E10) shows total APP and Ab species. (B) WB analysis using a soluble amyloid precursor protein a (sAPPa)-specific
antibody (2B3) or anti-N-terminal APP antibody (22C11) shows sAPPa or total APP, respectively. (C) WB analysis using pAb751/770 shows
full-length APP (holo APP) and 2 bands corresponding to b-carboxy terminal fragment and a-C-terminal fragment. (D) Mouse brain cortices
from each treatment group were stained with anti-phospho-tau (p-tau [Thr231]) antibody. In addition, percentages (p-tau [Thr231] positive
area/total area; mean + SD) of anti-p-tau antibody positive cells were quantified by ImageJ (1.47v, NIH, USA) analysis (**P < 0.005; data not
shown). WB data presented here are representative of results obtained from 5 to 6 female mice per group.

treatment. Our work is in line with the work of Villeda
et al.14 and Castellano et al.19, where improvement of performance in cognitive impairment was found in aged mice
treated with young plasma. Notwithstanding, we are not
quite sure how CBS fraction (aCBSF) ameliorates b-amyloid pathology and cognitive functioning in 5XFAD and tau
pathology in 3xTg-AD mouse model. The effect we
observe may or may not be from CBS a-secretase-like
enzyme. One of the plausible explanations for this effect
may be a direct action from CBS a-secretase-like enzyme
or could be an indirect effect through peripheral sink

hypothesis which demand further investigation. Although
we do not know the exact molecular mechanism, however,
we believe that human cord blood–derived serum and/or
plasma protein functions as a master regulator of several
genes involved in the proliferation of cells, and blood vessels that might reduce neuroinflammation, Ab, and improve
synaptic plasticity by affecting multiple pathways. Overall,
our results show beneficial effects of aCBSF in ameliorating b-amyloid pathology and cognitive functioning in
5XFAD and reducing tau phosphorylation in 3xTg-AD
mouse models.
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Fig. 9. Cord blood serum–specific fraction with enhanced a-secretase catalytic activity (aCBSF) reduces b-amyloid plaques in 5XFAD mice.
Five-month-old 5XFAD female mice were treated intraperitoneally with aCBSF (n ¼ 5 to 7) and aged blood serum fraction with enhanced asecretase activity (AgBSF; n ¼ 5 to 6) via osmotic mini pump at 30 mg/mouse/day for 6 wk. (A) Mouse brain sections from each group were
stained with 4G8, Congo red, and Thioflavin-S. (B) Percentages of 4G8 positive areas were quantified by ImageJ (1.47v, NIH, USA) analysis
for neocortex and hippocampus, showing that aCBSF treatment significantly reduced plaque area compared with AgBSF treatment (t-test
for independent samples; *P < 0.05, **P < 0.01).

Fig. 10. Neuroprotective effects of cord blood serum–specific fraction with enhanced a-secretase catalytic activity (aCBSF). 5XFAD mice
at 5 mo of age were treated intraperitoneally with aCBSF (n ¼ 7) or aged blood serum fraction with enhanced a-secretase activity (AgBSF;
n ¼ 6) via osmotic mini pump for 6 wk. (A) Mouse brain sections from aCBSF- and AgBSF-treated groups were stained with anti-NeuN
antibody. (B) Quantification of NeuN positive cells in the CA1, CA3, and neocortex revealed that aCBSF treatment significantly increased
NeuN-positive cells compared with AgBSF treatment in neocortex (t-test for independent samples; *P < 0.05).
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Fig. 11. Cord blood serum–specific fraction with enhanced a-secretase catalytic activity (aCBSF) improves cognitive function in 5XFAD
mice. Both male and female 5XFAD mice at 5 mo of age and age-matched nontransgenic wild-type (WT) controls (NTg) were treated with
aCBSF and aged blood serum fraction with enhanced a-secretase activity (AgBSF; 30 mg/mouse/day) intraperitoneally by osmotic mini pump
for 6 wk as described in the Methods and Materials section. Each treatment groups as well as nontransgenic WT controls (NTg) were
subjected to Novel Object Recognition and Y-maze behavioral testing. (A) Times spent exploring old and novel objects during the test phase
of novel object recognition was recorded for each treatment group. (B) Discrimination index, calculated as the frequency of exploring new
object versus original objects, was significantly reduced in 5XFAD mice treated with AgBSF, but not in those treated with aCBSF, compared
with NTg controls. (C) Total number of arm entries for Y-maze was recorded for each treatment group. (D) Percentage alternations was
significantly reduced in 5XFAD mice treated with AgBSF, but not in those treated with aCBSF, compared with NTg controls. Significance
level determined by analysis of variance for a total of n ¼ 5, NTg mice; n ¼ 6, aCBSF-treated 5XFAD mice; and n ¼ 6 AgBSF-treated 5XFAD
mice (***P < 0.001).

It is well known that members of the membrane-bound
zinc-dependent metalloproteinase ADAM family are asecretase enzymes that cleave APP for the nonamyloidogenic pathway. In particular, 3 different members of this
family, ADAM9, ADAM10, and ADAM17, possess APP
a-secretase activity31. The ADAM family constitutes a large
family of multidomain membrane proteins that have
cysteine-rich, disintegrin, and zinc metalloprotease domains
in their ectodomain32. The main function of ADAM family
is to shed the ectodomain of different membrane proteins
and has growth factors-like function via intracellular signaling cascade. However, it should be noted that numerous
other substrates also have been linked to this ADAM family.
These functions of ADAM family either protect against AD
or promote AD pathogenesis via activation of different

cytokines. One of the enzymes, ADAM17, is also known
as TACE, responsible for secreting the main proinflammatory cytokine, TNFa33. Thus, TACE (ADAM17)
is a therapeutic target for multiple diseases. Additionally,
both ADAM10 and ADAM17 cleave various other membrane proteins and promote tumor in the cell34. ADAM10,
in particular, cleaves many different kinds of transmembrane
proteins in the vascular system, including the plateletactivating collagen receptor glycoprotein VI 35,36 , and
endothelial proteins, including transmembrane chemokines
(i.e., CX3CL1 and CXCL16)37. These 2 chemokines are
known for angiogenesis, inflammation, and immune cell
recruitment38,39. Likewise, ADAM9 cleaves and releases a
number of molecules with important roles in tumorigenesis
and angiogenesis. Taken together, whereas the known
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a-secretase enzymes, mainly ADAM10 and ADAM17
(TACE) and in some degree ADAM9, are involved in APP
a-secretase cleavage, they are not APP-specific and cleave
various substrates associated with inflammation, tumor formation, and progression. Thus, whereas AD is the only
pathology in which an increased a-secretase activity has
been proposed to be favorable, the nonspecific nature of the
known a-secretases has made this strategy for AD treatment
thus far unsuitable40.
In sum, our study has presumably discovered an umbilical
cord blood–derived a-secretase that is independent of TACE
or ADAM, thus making it a suitable candidate for the further
study as a therapeutic target for AD treatment. This asecretase-like enzyme activity either directly or indirectly
activates a-secretase or produces sAPPa in cell culture and
AD animal models. In addition, we believe this a-secretase
appears to be mediated by novel enzymes residing within the
sera which decline with age. We expect that our study using
fractionation, chromatographic separation, and massspectrometry (MS) techniques would identify the target
enzyme as well as other interacting partners from CBS.
However, identification of a target protein or enzyme with
a particular function from a complex mixture of serum is a
challenging task due to multiple factors including the high
complexity and wide dynamic range of proteins as well as
the presence of contaminating proteins of high abundance.
Despite this, here we show that our purification techniques
significantly enhanced the a-secretase of CBS. Further, MSbased sophisticated purification techniques will completely
purify, identify, and characterize the factor mediating this asecretase in CBS.
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